Exposure‐response relationships of etrolizumab in patients with moderately‐to‐severely active ulcerative colitis

• Autori principali: Nastya Kassir (Autore), Rui Zhu (Autore), Anita Moein (Autore), Jurgen Langenhorst (Autore), Jakob Ribbing (Autore), Rong Zhang (Autore), Meina T. Tang (Autore), Young S. Oh (Autore), Wenhui Zhang (Autore)
• Natura: Libro
• Pubblicazione: Wiley, 2022-09-01T00:00:00Z.
• Soggetti: article
• Accesso online: Connect to this object online.

Abstract Etrolizumab is an IgG1‐humanized monoclonal anti‐β7 integrin antibody. Phase III trials with induction and/or maintenance phases were conducted in patients with moderately‐to‐severely active ulcerative colitis (UC) who were either previously treated with tumor necrosis factor (TNF) inhibito...